-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Merck & Co. Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$41.52 B | $48.70 B | $59.28 B | $60.12 B | $64.17 B |
| Cost of Revenue |
|
$13.62 B | $13.63 B | $17.41 B | $16.13 B | $12.29 B |
| Gross Profit |
|
$27.90 B | $35.08 B | $41.87 B | $43.99 B | $51.88 B |
| Research & Development |
|
$13.40 B | $12.25 B | $13.55 B | $30.53 B | $17.94 B |
| Selling,General & Administrative |
|
$8.96 B | $9.63 B | $10.04 B | $10.50 B | $11.25 B |
| Operating Expense |
|
$22.35 B | $21.88 B | $23.59 B | $40.91 B | $29.19 B |
| Operating Income |
|
$6.08 B | $13.70 B | $19.40 B | $2.95 B | $22.69 B |
| Net Income |
|
$7.07 B | $13.05 B | $14.52 B | $365.00 M | $17.12 B |
Merck & Co. Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$8.06 B | $8.10 B | $13.19 B | $7.09 B | $13.69 B |
| Inventories |
|
$6.31 B | $5.95 B | $5.91 B | $6.36 B | $6.11 B |
| Total Current Assets |
|
$27.76 B | $30.27 B | $35.72 B | $32.17 B | $38.78 B |
| Property,Plant and Equipment |
|
$17.99 B | $19.28 B | $21.42 B | $24.49 B | - |
| Goodwill |
|
$20.24 B | $21.26 B | $21.20 B | $21.20 B | $21.67 B |
| Total Assets |
|
$91.59 B | $105.69 B | $109.16 B | $106.68 B | $77.28 B |
| Total Liabilities |
|
$66.18 B | $67.44 B | $63.10 B | $69.04 B | $30.97 B |
| Retained Earnings |
|
$47.36 B | $53.70 B | $61.08 B | $53.90 B | - |
| Total Shareholder Equity |
|
$25.32 B | $38.18 B | $45.99 B | $37.58 B | $46.31 B |
| Common Stock |
|
$1.79 B | $1.79 B | $1.79 B | $1.79 B | - |
Merck & Co. Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$3.63 B | $3.21 B | $3.91 B | $3.87 B | $4.50 B |
| Dividends Payout |
|
-$6.22 B | -$6.61 B | -$7.01 B | -$7.45 B | -$7.84 B |
| Capital Expenditures (Capex) |
|
-$4.68 B | -$4.45 B | -$4.39 B | -$3.86 B | -$3.37 B |
| Free Cash Flow (FCF) |
|
$5.57 B | $9.66 B | $14.71 B | $9.14 B | $18.10 B |
Merck & Co. Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$27.90 B | $35.08 B | $41.87 B | $43.99 B | $51.88 B |
| Gross Profit Margin (%) |
|
67.20% | 72.02% | 70.63% | 73.17% | 80.85% |
| Operating Income |
|
$6.08 B | $13.70 B | $19.40 B | $2.95 B | $22.69 B |
| Operating Income Margin (%) |
|
14.63% | 28.14% | 32.72% | 4.91% | 35.36% |
| Net Income |
|
$7.07 B | $13.05 B | $14.52 B | $365.00 M | $17.12 B |
| Net Income Margin (%) |
|
17.02% | 26.79% | 24.49% | 0.61% | 26.68% |
| EBITDA |
|
$10.18 B | $17.90 B | $21.32 B | $6.91 B | $26.94 B |
| EBITDA Margin (%) |
|
24.52% | 36.75% | 35.95% | 11.49% | 41.98% |
Merck & Co. Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
27.91% | 34.17% | 31.57% | 0.97% | 36.96% |
| Return on Assets (ROA) |
|
7.72% | 12.35% | 13.30% | 0.34% | 22.15% |
| Debt to Equity |
|
125.57% | 86.69% | 66.73% | 96.51% | 80.13% |
| Debt to total asset |
|
34.71% | 31.32% | 28.12% | 34.00% | 48.02% |
| Enterprise value to revenue |
|
5.32 | 4.49 | 5.04 | 5.22 | 4.31 |
| Enterprise value to EBITDA |
|
21.72 | 12.23 | 14.02 | 45.41 | 10.27 |
| Enterprise value |
|
$221.07 B | $218.91 B | $298.92 B | $313.66 B | $276.65 B |
| Cash to Debt |
|
32.25% | 42.62% | 62.22% | 35.86% | 57.85% |
| Tax Rate (%) |
|
19.44% | 10.96% | 11.66% | 80.04% | 14.06% |
| Payout Ratio |
|
87.94% | 50.66% | 48.30% | 2,039.73% | 45.80% |
